Irene Gazzo

Dr. Irene Gazzo

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 November 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
ACAngelo Cagnacci
Angelo Cagnacci
IGIrene Gazzo
Irene Gazzo
SSSara Stigliani
Sara Stigliani
APAnna Maria Paoletti
Anna Maria Paoletti
PAPaola Anserini
Paola Anserini
AXAnjeza Xholli
Anjeza Xholli
The effect of estrogen and progesterone on oxidative status is not yet very clear, improvements and detrimental effects having been reported with the use of menopausal hormone therapy or hormonal contraceptives, respectively. In this study, we evaluated the role played by estrogen and progesterone separately, on the oxidative status of 32 women, 18 to 43 years old, by inducing high levels of estrogen and then adding high levels of progesterone. During a cycle of in vitro fertilization, blood samples were collected prior to gonadotrophin stimulation (low estradiol levels), on the day of oocyte retrieval (high levels of estrogen), and on the day of embryo transfer (high levels of estrogen and progesterone). Total blood levels of oxidants (FORT), antioxidants (FORD), and their ratio FORT/FORD were measured using a colorimetric method based on the Fenton reaction. Seven women measured their early morning body temperature at the same time points. FORT significantly decreased from the low- to the high-estrogen phase (p = 0.023) and increased from the high-estrogen to the high-estrogen–progesterone phase (p = 0.006). FORD showed an opposite but non-significant trend. The FORT/FORD ratio decreased from the low- to the high-estrogen phase (p = 0.0104) and increased from the high-estrogen to the high-estrogen –progesterone phase (p = 0.004). Body temperature (n = 7) decreased in the high-estrogen phase (p = 0.001) and increased from the high-estrogen to the high-estrogen–progesterone phase (p = 0.001). In the seven women, FORT (p = 0.009) and FORT/FORD (p = 0.0056) were linearly related to body temperature values. Our data show opposite effects of estrogen and progesterone on oxidative status. These effects seem to be related to the effect exerted on body temperature regulation.

19 November 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
CMClaudia Massarotti
Claudia Massarotti
ESElvira Sbragia
Elvira Sbragia
IGIrene Gazzo
Irene Gazzo
SSSara Stigliani
Sara Stigliani
MIMatilde Inglese
Matilde Inglese
PAPaola Anserini
Paola Anserini
Multiple sclerosis is a chronic disease that may lead to different types of symptoms and disabilities. with the better quality of life and decreased disability due to early diagnosis and the availability of disease-modifying therapies (DMTs), the treating physician is increasingly asked to counsel patients on its effects on fertility and reproduction. In particular, reproductive issues are still scarcely studied and discussed in men. Among the still open questions are the following: (a) Does multiple sclerosis cause infertility per sè? (b) Is multiple sclerosis correlated with conditions that increase the risk of infertility? (c) Do DMTs or other therapies for multiple sclerosis impact gonadal function in men? The aim of this review is to provide an overview on the available literature data about the reproductive issues unique to men with multiple sclerosis, underlining the numerous areas where evidence is lacking and, therefore, the priorities for future research.

16 August 2022 in The World Journal of Men's Health
Verified
Journal Article
Open access
PDF file
CMClaudia Massarotti
Claudia Massarotti
SSSara Stigliani
Sara Stigliani
EMElena Maccarini
Elena Maccarini
FBFrancesca Bovis
Francesca Bovis
MFMattia Francesco Ferraro
Mattia Francesco Ferraro
PSPaola Scaruffi
Paola Scaruffi
Massarotti C, et al. World J Mens Health. 2022 Aug;40:e54. https://doi.org/10.5534/wjmh.220055

16 May 2024 in Best Practice & Research Clinical Obstetrics & Gynaecology
Verified
Journal Article
Open access
IGIrene Gazzo
Irene Gazzo
FMFederica Moffa
Federica Moffa
Simone FerreroSimone Ferrero
Simone Ferrero
In recent years, advancements in cryopreservation techniques for oocytes, embryos, and ovarian tissue have enabled offering fertility preservation (FP) options to women with endometriosis. It is recommended to always conduct specialized counselling on FP, especially before considering surgical interventions for endometriosis. The decision regarding the methods of FP, the timing, and to which women affected by endometriosis these techniques should be offered are still subjects of discussion. However, several studies suggest that it can be proposed before surgical interventions for endometriosis, particularly if the patient is undergoing mono or bilateral endometrioma surgery. The most recommended technique is ovarian stimulation, followed by oocyte cryopreservation. Nevertheless, the literature contains various studies describing FP through embryo cryopreservation or the retrieval and cryopreservation of ovarian tissue.

1 January 2024 in Reproduction and Fertility
Verified
Journal Article
Open access
PDF file
IGIrene Gazzo
Irene Gazzo
FBFrancesca Bovis
Francesca Bovis
DCDenise Colia
Denise Colia
FSFausta Sozzi
Fausta Sozzi
MCMauro Costa
Mauro Costa
CMClaudia Massarotti
Claudia Massarotti
In the registration trials, follitropin delta was compared with a fixed dose of 150 UI of follitropin alpha/beta, finding higher chances to reach a target response of 8–14 oocytes compared to controls. For this reason, follitropin delta is marketed as particularly useful in expected hyper-responder patients. The main outcome of this study is to report if comparable results are reached in a real-life scenario with follitropin alpha/beta doses chosen by the physician, based on patients’ characteristics. This is a retrospective study performed in two public fertility centres. All first cycles from January 2020 to June 2022 with either follitropin delta (cases) or alpha/beta (controls) in patients with anti-Müllerian hormone >2.5 ng/mL were compared by an inverse probability weighting approach based on propensity score. The follitropin total dose was higher in controls (1179.06 ± 344.93 vs 1668.67 ± 555.22 IU, P < 0.001). The target response of 8–14 oocytes was reached by 40.2% of cases and 40.7% of controls (odds ratio (OR): 0.99, 95% confidence interval (CI): 0.65–1.53, P = 0.98). Fewer than 8 oocytes were collected in 24.1% of cases and 22% of controls (OR: 1.10, 95% CI: 0.71–1.69, P = 0.67); more than 14 oocytes in 35.7% of cases and 37.3% of controls (OR: 0.83, 95% CI: 0.54–1.28, P = 0.40). Our experience did not find worse results in term of proportion of patients who reached the target response with an algorithm-chosen dose of follitropin delta compared to a personalised starting dose of follitropin alpha/beta, with follitropin delta having the advantage of objectivity. However, larger numbers are needed to confirm these results. Lay summary: The starting dose of the drugs used to stimulate the ovaries in IVF (gonadotropins) is usually decided by the doctor, using their clinical experience and expertise and tailored to the individual patient. Recently one type of stimulating drug (follitropin delta) was marketed with an algorithm for deciding the starting dose based on the patient’s anti-Müllerian hormone (AMH) levels and weight. In the initial trials, it was compared with a fixed dose of standard follitropins (alpha/beta), and it was found to reduce the likelihood of an excessive response in patients at risk of ovarian hyperstimulation syndrome. We report on these results, in terms of number of eggs obtained, in patients with an expected high ovarian response, compared to doses of standard follitropins that were not fixed, but personalised, to see if this did not make a difference. We found similar results in the two groups, suggesting that using the algorithm to decide the dose of follitropin delta does not work less well than a personalised starting dose of follitropin alpha/beta, but has the advantage of being objective.

22 January 2026 in International Journal of Gynecology & Obstetrics
Verified
Journal Article
Open access
Fabio BarraFabio Barra
Fabio Barra
IGIrene Gazzo
Irene Gazzo
Alessandro FavilliAlessandro Favilli
Alessandro Favilli
CRConsuelo Russo
Consuelo Russo
GMGiulia Monaco
Giulia Monaco
Simone FerreroSimone Ferrero
Simone Ferrero
A T‐shaped uterus is a uterine malformation, which can be either congenital or acquired, potentially impairing fertility and increasing the risk of miscarriage. Diagnosis primarily relies on three‐dimensional ultrasound and hysteroscopy. Hysteroscopic metroplasty is the standard surgical intervention aimed at restoring normal uterine anatomy and potentially improving reproductive outcomes. This narrative review, conducted in accordance with SANRA (Scale for the Assessment of Narrative Review Articles) guidelines, is based on a comprehensive database search and critically evaluates observational and interventional studies on the definition, diagnosis, and management of T‐shaped uterus in the context of in vitro fertilization. Recent studies indicate that correction of this anomaly might not only improve spontaneous conception rates but also enhance the outcomes of IVF. However, the precise role of metroplasty in patients undergoing IVF outcomes remains controversial. Some evidence indicates that surgical correction might improve embryo implantation and endometrial perfusion. Despite these promising observations, randomized controlled trials are necessary to define optimal patient selection criteria and to confirm the true benefit of metroplasty in the context of IVF. Future research should also address the potential risks associated with the procedure. A standardized diagnostic and therapeutic approach might contribute to improved reproductive outcomes in affected patients.